로그인
토토사이트
먹튀사이트/제보
업체홍보/구인
신규사이트
지식/노하우
놀이터홍보
판매의뢰
스포츠분석
뉴스
후기내역공유
커뮤니티
포토
포인트
보증업체
카지노 먹튀
토토 먹튀
먹튀제보
구인
구직
총판
제작업체홍보
카지노
토토
홀덤
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
토토 홍보
카지노 홍보
홀덤 홍보
꽁머니홍보
신규가입머니
제작판매
제작의뢰
게임
축구
야구
농구
배구
하키
미식축구
스포츠뉴스
연예뉴스
IT뉴스
카지노 후기
토토 후기
홀덤 후기
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[]
생고기 썬 칼, 수세미로 ‘싹싹’ 닦고 있나요?…무심코 한 설거지가 식중독 부른다
N
[IT뉴스]
“공 들여 만든 에이전트가 기밀 퍼준다”...‘AI 해킹’ 시대 달라진 보안 문법 [허진의 테크토닉]
N
[IT뉴스]
김범수 2심도 무죄…카카오 AI사업 날개달까
N
[IT뉴스]
Hanmi’s Obesity Drug Epe Sells Out in Record Time[K-Bio Pulse]
N
[IT뉴스]
최태원 SK회장, "한일 기업·대학 AI인재 공동플랫폼 만들자"
N
커뮤니티
더보기
[유머★이슈]
바란 은퇴보다 더 소름돋는점
[유머★이슈]
오늘 국군의날 예행연습에 최초 공개된 장비들
[유머★이슈]
손흥민이 한국 병역 시스템에 영향 끼친 것.
[유머★이슈]
시댁의 속터지는 스무고개식 대화법
[유머★이슈]
엄마. 나 여자 임신시켜버렸어
목록
글쓰기
[IT뉴스]Hanmi’s Obesity Drug Epe Sells Out in Record Time[K-Bio Pulse]
온카뱅크관리자
조회:
7
2026-11-22 08:37:25
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="fLpowmoMIy"> <div contents-hash="7ca9c10283e76ffa5de438d07b4f4a2f81e9ab1b86307b0694e50b48d7203b2b" dmcf-pid="4PGQoaQ9IT" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on November 21, 2026, at 8:30 AM. </div> </div> <p contents-hash="db653ce722836a98971d59ae800084897c75c0e69bf042422c2ee095d8a65446" dmcf-pid="8QHxgNx2Iv" dmcf-ptype="general">[Jiwan Kim, Edaily Reporter] Despite a sharp decline in South Korea's stock market on November 20, Hanmi Pharmaceutical rose more than 6% on strong initial demand for its domestically developed obesity drug, Epe. </p> <p contents-hash="587ef53e67661cd6c12a7b1c1ba12507ba894bfca39d27413096d131de7c5d13" dmcf-pid="6xXMajMVmS" dmcf-ptype="general">HK inno.N also closed higher amid expectations for U.S. FDA approval of its gastroesophageal reflux disease treatment, K-CAB, in January 2027. Meanwhile, Bioneer attracted investor interest with its proprietary RNA interference (RNAi) platform and potential global licensing opportunities.</p> <figure class="figure_frm origin_fig" contents-hash="b5cd5a022d6cf98d468668754288e39fced5889ee8f037ed8e36dfcd88815981" dmcf-pid="PMZRNARfDl" dmcf-ptype="figure"> <p class="link_figure"><img alt="(Graphic by ChatGPT)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202611/22/Edaily/20261122083237023ejzr.png" data-org-width="1122" dmcf-mid="Kq6PLgPKmH" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202611/22/Edaily/20261122083237023ejzr.png" width="658"></p> <figcaption class="txt_caption default_figure"> (Graphic by ChatGPT) </figcaption> </figure> <p contents-hash="45964cd36d5080c2c22b207b6ffdf8ce61b50cc97a8676ad2e3c430f77315e1f" dmcf-pid="QR5ejce4wh" dmcf-ptype="general">The pharmaceutical sector declined 1.34%, while the biotechnology sector fell 2.50%. Among 161 pharmaceutical stocks, only 18 advanced, while 131 ended lower. In the biotechnology sector, 68 of 93 stocks closed below their previous trading day's levels.</p> <p contents-hash="7fb759d04e4b7b518910e11d9d421d00893dae46b22f4d82bbc718adbe5e047f" dmcf-pid="xe1dAkd8rC" dmcf-ptype="general"><strong>Hanmi’s Obesity Drug Epe Sells Out Initial Supply</strong></p> <p contents-hash="5868852a630b0f211325a3bf54d5480c2108b69e2b7a529dbb0ae620486559f7" dmcf-pid="yGLHU7HlDI" dmcf-ptype="general">Hanmi Pharmaceutical surged after reports that the initial supply of its domestically developed obesity treatment, Epe, worth approximately KRW 10 billion, had been exhausted ahead of expectations. The rapid depletion of initial inventory following the start of domestic prescriptions fueled optimism about future sales growth.</p> <p contents-hash="05305c26815b70f01799967aeaa7edfac6d7caa087b24ee27ce488eb43f031d4" dmcf-pid="WHoXuzXSmO" dmcf-ptype="general">According to KG Zeroin's MP Doctor, Hanmi Pharmaceutical closed at KRW 449,000, up KRW 27,000, or 6.40%, from the previous session. Its strong performance contrasted with a broader market selloff that saw both the KOSPI and KOSDAQ indices plunge more than 5% during intraday trading.</p> <p contents-hash="ba434d714baf077a69cca32f6a6e6e428be1bbbc91cf242cb4b1e37c75260824" dmcf-pid="YHoXuzXSDs" dmcf-ptype="general">The primary driver behind the rally was growing confidence in Epe's commercial potential. The drug, which became available for domestic prescriptions on October 29, exhausted its initial supply worth approximately KRW 10 billion within two business weeks.</p> <p contents-hash="cfe4ccf0d8579a64be4a16d60edb5166b48c63942ae497c59c4b2a4b75f90572" dmcf-pid="GXgZ7qZvsm" dmcf-ptype="general">Analysts attributed the strong early demand partly to Hanmi's competitive pricing strategy. The introductory four-week supply price was set at KRW 129,800, roughly half that of competing obesity treatment Mounjaro.</p> <p contents-hash="a447cb231eba519251502b141c7f55b159166ff0b818d94491fb8c85ef9093c8" dmcf-pid="HZa5zB5TOr" dmcf-ptype="general">Recent clinical data further strengthened investor confidence. On November 16, Hanmi presented 64-week results from Epe's Phase 3 clinical trial involving 448 Korean adults with obesity or overweight at a U.S. obesity conference.</p> <p contents-hash="9fc65d4eb6293766110d2176ef60559c9f4d24128ab7981eb433f63466054eca" dmcf-pid="X5N1qb1yww" dmcf-ptype="general">The average weight reduction reached 10.56%, an improvement of 0.81 percentage points from the previously reported 9.75% reduction at 40 weeks.</p> <p contents-hash="cf2e688a0031d4af15861b656862b6d10b1ee70ac011e464e65382aa096001d6" dmcf-pid="Z1jtBKtWwD" dmcf-ptype="general">Expectations surrounding Hanmi's next-generation obesity drug pipeline also supported the stock.</p> <figure class="figure_frm origin_fig" contents-hash="8a84495f3e965c11cc9ab7e9074640eff8c2faef6b1afa9c473789f3b6625008" dmcf-pid="5tAFb9FYsE" dmcf-ptype="figure"> <p class="link_figure"><img alt="Hanmi Pharmaceutical’s Epe, South Korea’s first domestically developed GLP-1 obesity drug. (Photo courtesy of Hanmi Pharmaceutical)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202611/22/Edaily/20261122083238302bene.jpg" data-org-width="742" dmcf-mid="97TyF0yOsG" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202611/22/Edaily/20261122083238302bene.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Hanmi Pharmaceutical’s Epe, South Korea’s first domestically developed GLP-1 obesity drug. (Photo courtesy of Hanmi Pharmaceutical) </figcaption> </figure> <div contents-hash="bf73103fec692132983f869e4eca34d8f5695c60ecab013e5d1da332333324da" dmcf-pid="1Fc3K23GOk" dmcf-ptype="general"> KB Securities maintained its Buy rating and KRW 650,000 price target, representing approximately 54% upside from the previous closing price. </div> <p contents-hash="733e62646c7c3dc4d41fcbef9af3d5654f5281e092ccab2ed998cbd4c63421c1" dmcf-pid="t3k09V0Hsc" dmcf-ptype="general">Shin Ji-hoon, an analyst at KB Securities, projected that Hanmi's triple-agonist obesity drug candidate, zantrutide (HM15275), could attract licensing opportunities following the anticipated completion of its U.S. Phase 2 trial in the first half of 2027.</p> <p contents-hash="ee6edf725d76fa83a68907849bbf7adee40b07777e277967423705e714ac0d5c" dmcf-pid="F0Ep2fpXsA" dmcf-ptype="general">Another obesity treatment candidate, HM17321, already licensed to Roche, is also expected to complete Phase 1 clinical trials during the same period.</p> <p contents-hash="a126aa6d5ff77edb77b04b960339fa10e8f03c880054a09b5742c170dabcc287" dmcf-pid="3HoXuzXSmj" dmcf-ptype="general">Hanmi plans to build on Epe's early market momentum by gradually expanding production and broadening its distribution network to hospitals, clinics and pharmacies nationwide starting in January 2027.</p> <p contents-hash="30687572e834b5e444ba0b121676e584bb3b5333513b81ab7208469fbf109db7" dmcf-pid="0XgZ7qZvDN" dmcf-ptype="general">A Hanmi Pharmaceutical official said, "Our medium- to long-term goal is to increase Epe sales to KRW 200 billion."</p> <p contents-hash="da4fdbdf07cf5157ed38dcdb04eae5b8f9a5ced53ec6130ee905aed01dde3d17" dmcf-pid="pZa5zB5TOa" dmcf-ptype="general">HK inno.N Gains 2.26% on Expectations for U.S. Approval of K-CAB and 23% Earnings Growth</p> <p contents-hash="c0390f28a9d86edee57c92a03f03977e8783a68a2a3c046818da49efd8c06bc9" dmcf-pid="U5N1qb1yIg" dmcf-ptype="general">HK inno.N closed higher on growing expectations for the U.S. market entry of K-CAB, its treatment for gastroesophageal reflux disease. The anticipated FDA decision in January 2027, combined with a recovery in domestic sales, has strengthened expectations for improved earnings.</p> <p contents-hash="c49a1402ea816681f5b2f4767c2ff5528f5d2bbd278cc02cb3a0206e724bb18c" dmcf-pid="u1jtBKtWDo" dmcf-ptype="general"><strong>HK inno.N Eyes U.S. Market Entry With K-CAB in 2027</strong></p> <p contents-hash="d9b4d0e21bca28dc7474b46a09348badd3808960fe1c52316d81835fb7089130" dmcf-pid="7tAFb9FYOL" dmcf-ptype="general">The potential U.S. launch of K-CAB was a key factor behind investor optimism.</p> <p contents-hash="4dc1542a54b5de551b7216dbd5b2dad320ba2a8391eab92ad39c70771ecee420" dmcf-pid="zFc3K23Gwn" dmcf-ptype="general">KB Securities maintained its Buy rating and KRW 70,000 price target for HK inno.N. The brokerage forecast 2027 revenue of KRW 1.1204 trillion, representing a 4.4% year-on-year increase, and operating profit of KRW 159.2 billion, up 22.8%.</p> <p contents-hash="bf996692a49759b55693a103d6125835a13385f205ea40becdad15dc939f3574" dmcf-pid="q3k09V0HOi" dmcf-ptype="general">K-CAB's U.S. entry is considered a major potential catalyst for the company's valuation.</p> <p contents-hash="78bb9a7bcea5c6520a1f37e87429f3c39471ac0cbb064fc1cbf3b11f2798e956" dmcf-pid="B0Ep2fpXIJ" dmcf-ptype="general">If the drug receives FDA approval in January 2027, HK inno.N is expected to begin receiving milestone payments and royalties tied to U.S. sales. KB Securities projected that annual U.S. sales of K-CAB could reach approximately USD 400 million by 2031.</p> <p contents-hash="ecd9c277004af6f2a59dd74d06791b3e992f917d0e0ee5f34242e87d354655d8" dmcf-pid="bPGQoaQ9Dd" dmcf-ptype="general">The U.S. market environment is also becoming more favorable.</p> <p contents-hash="902e2b66a3b364abbb8c19a55ea25612053507f2913bfa31e1a903a71ff24092" dmcf-pid="KQHxgNx2re" dmcf-ptype="general">Voquezna, a competing treatment in the same potassium-competitive acid blocker (P-CAB) class, generated USD 84.7 million in third-quarter revenue, an increase of 71% from a year earlier.</p> <p contents-hash="34f604f332d020f5d0f2839650811639eacf88cdd009f7e8472644e0cff86309" dmcf-pid="9xXMajMVDR" dmcf-ptype="general">Analysts believe the commercial progress of existing P-CAB treatments could reduce market entry barriers for K-CAB by increasing physician awareness and establishing prescribing practices.</p> <figure class="figure_frm origin_fig" contents-hash="6d57c4e053d543f5fe6e938f7a8e8712b5d3a47ebb9bf4a05b1683ac5b83bcb7" dmcf-pid="2MZRNARfmM" dmcf-ptype="figure"> <p class="link_figure"><img alt="K-CAB. (Photo=HK inno.N)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202611/22/Edaily/20261122083239517fbie.jpg" data-org-width="1000" dmcf-mid="2IFikDiPrY" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202611/22/Edaily/20261122083239517fbie.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> K-CAB. (Photo=HK inno.N) </figcaption> </figure> <p contents-hash="f912c2e7e70db33c441e345273522eff2b333d4b845cf38b8e794e314c1ae845" dmcf-pid="VR5ejce4wx" dmcf-ptype="general">Domestic business performance is also expected to improve.</p> <p contents-hash="f16b9ffd593eb76ffed4e8e8597c2538a884203f76717b55eaf1a12457553388" dmcf-pid="fe1dAkd8DQ" dmcf-ptype="general">K-CAB's third-quarter outpatient prescription value reached KRW 65.4 billion, up 16.5% year-on-year. However, reported domestic revenue declined 15% due to drug-price rebate accounting adjustments and inventory management.</p> <p contents-hash="73eabfec1f86f11aa2e46edeb7226f8a2c053da5d32e52f5fe9220099e0be4dd" dmcf-pid="4dtJcEJ6mP" dmcf-ptype="general">Analysts expect these temporary factors to ease, allowing prescription growth to translate more directly into revenue expansion in 2027.</p> <p contents-hash="e3ea2269b774471e061e38ef99b9d4d6cedfa5230797566ceeba1366b2b95d59" dmcf-pid="8JFikDiPs6" dmcf-ptype="general">Shin Ji-hoon of KB Securities said, "The fact that existing treatments have already experienced the challenges of entering the U.S. market, while improving insurance coverage procedures and physician awareness, is positive."</p> <p contents-hash="bce5a3dd613a6725471af81e7934230066fbda275547f6133635b67e883701dc" dmcf-pid="6i3nEwnQw8" dmcf-ptype="general">He added, "K-CAB will enter a market where much of the groundwork has already been laid, giving it an advantage during the initial launch period."</p> <p contents-hash="6012d12d1a90f21ae1cc45f80f5c784f53b41a245ce6f398f6bb99e5980925e1" dmcf-pid="PO6IGXIkO4" dmcf-ptype="general">Bioneer Highlights RNAi Drug Platform in Europe, Explores Global Licensing Opportunities</p> <p contents-hash="49b3281e9e65f4c8921c77ab61daa28b48de7cf9abc8c83d6c70ad88c9ba3862" dmcf-pid="QIPCHZCEIf" dmcf-ptype="general">Bioneer sought to expand international collaboration opportunities by presenting its proprietary RNA interference technology at one of Europe's largest pharmaceutical and biotechnology partnering events.</p> <p contents-hash="28557fadae8da5da65d5c24b7ac3fff0f6613c408029983cde50b656eefa6495" dmcf-pid="xCQhX5hDrV" dmcf-ptype="general">The company announced on November 20 that it had conducted approximately 20 one-on-one meetings with global pharmaceutical companies and major European medical institutions during BIO-Europe 2026, recently held in Cologne, Germany.</p> <p contents-hash="e893fe0c9bbb8295b3bc2b24d5daf37a39057787b6ea275017966745faaca439" dmcf-pid="yfT4Jn4qO2" dmcf-ptype="general"><strong>Bioneer Eyes Global Deals for RNAi Platform</strong></p> <p contents-hash="820f80fc28b02f8486881a09d0ac62fd8599c8a8e6eb879ab5db2848977946aa" dmcf-pid="W4y8iL8BD9" dmcf-ptype="general">At the event, Bioneer highlighted its proprietary SAMiRNA platform, which uses nanoparticles to deliver small interfering RNA (siRNA) to targeted tissues.</p> <p contents-hash="68ef66e8f8eaa39559327657882d3d59c656e5a5d1163c5516900564025f2425" dmcf-pid="Y8W6no6bsK" dmcf-ptype="general">The technology is designed for localized administration, reducing systemic exposure while delivering therapeutic effects to specific tissues.</p> <p contents-hash="6b66c25ecd0243d31b02f0bf4bb40473a3790eda663c11ee516936056ffc35f1" dmcf-pid="G6YPLgPKrb" dmcf-ptype="general">Bioneer has already commercialized CosmeRNA, a hair-care cosmetic product based on the platform. The company is now developing a next-generation hair-loss treatment designed to act directly on hair follicles.</p> <figure class="figure_frm origin_fig" contents-hash="e03a92d54971cc9118ed1f364ec458379f9aa6c04f9676116e84d6d0441ad2e6" dmcf-pid="HPGQoaQ9DB" dmcf-ptype="figure"> <p class="link_figure"><img alt="CosmeRNA. (Photo=Bioneer)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202611/22/Edaily/20261122083240729xrxi.jpg" data-org-width="670" dmcf-mid="VcBcClcnwW" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202611/22/Edaily/20261122083240729xrxi.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> CosmeRNA. (Photo=Bioneer) </figcaption> </figure> <p contents-hash="2c3ff1afa5ceee0c2ffe86491ed79732703ebaf3b07a0b737c61ed5ec4a06100" dmcf-pid="XQHxgNx2mq" dmcf-ptype="general">Its objective is to address potential hormone-related systemic side effects associated with conventional oral hair-loss medications.</p> <p contents-hash="e274f8c5126329c32b15d4d31c549bd124a52000446e36c1a58e929dc56d3ed4" dmcf-pid="Z3k09V0Hrz" dmcf-ptype="general">Another major focus of the partnering discussions was SRN001, an investigational treatment for fibrotic diseases.</p> <p contents-hash="6294eb6543a64ea5720cf10d25f2f3ff7fa77925eef7ebeba7a55620b0157c45" dmcf-pid="50Ep2fpXE7" dmcf-ptype="general">SRN001 is designed to selectively inhibit amphiregulin (AREG), a protein associated with fibrosis. The candidate is currently undergoing the multiple ascending dose portion of a Phase 1b clinical trial.</p> <p contents-hash="b594401c1354f8e7ea1940e9e22eced476e60bb51cbfcd7c095511c472379241" dmcf-pid="1pDUV4UZIu" dmcf-ptype="general">Bioneer plans to advance discussions with global pharmaceutical companies regarding potential licensing agreements once additional clinical data become available.</p> <p contents-hash="6fa04a858be7da51bcaa1cea2f27ad67500c377b6481ae7badd0c3f22db3f6b2" dmcf-pid="tUwuf8u5OU" dmcf-ptype="general">The company also held meetings with three major European hospitals to explore opportunities in molecular diagnostics.</p> <p contents-hash="c2c44ac2716eb0406c99bf870d0722e984fcfd89ea6e81dd4ab84c0b66fb56c4" dmcf-pid="Fur74671Op" dmcf-ptype="general">Bioneer introduced its point-of-care molecular diagnostic system, IRON-qPCR, and its automated high-throughput molecular diagnostic platform, ExiStation FA 96. Discussions included potential clinical evaluations of the equipment at European medical institutions.</p> <p contents-hash="8a8f48e3a04b5e784f47aaf6b03df8b4c4951af7de30d4e3ed2a3ae47ee175f5" dmcf-pid="37mz8Pztm0" dmcf-ptype="general">A Bioneer official said, "Global RNAi drug development is shifting its focus beyond liver diseases toward extrahepatic tissues, including fat, muscle, lungs and skin."</p> <p contents-hash="2d40ff19cc0bf9f7686526696f10b723b90c491e208375c727135a76f0f2e114" dmcf-pid="0zsq6QqFI3" dmcf-ptype="general">The official added, "We will continue follow-up discussions with the partners we met at the event and demonstrate tangible progress through SRN001 clinical data and molecular diagnostic evaluations."</p> <p contents-hash="273cc52098e78db35838db576386bd68fdf873a680fda4b573e650f926dad614" dmcf-pid="pqOBPxB3EF" dmcf-ptype="general">김지완 (2pac@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
놀이터홍보
더보기
[홀덤 홍보]
텍사스홀덤 핸드 순위- 홀카드의 가치
[홀덤 홍보]
텍사스홀덤 핸드 순위 - 프리플랍(Pre-Flop) 핸드 랭킹
[토토 홍보]
미니게임개발제작 전문업체 포유소프트를 추천드립니다.
[토토 홍보]
2023년 일본 만화 판매량 순위 공개
[토토 홍보]
무료만화 사이트 보는곳 3가지 추천
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기